Mediwound (MDWD) to Release Quarterly Earnings on Tuesday

Mediwound (NASDAQ:MDWD) will announce its earnings results before the market opens on Tuesday, May 21st. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.

Mediwound (NASDAQ:MDWD) last issued its earnings results on Monday, March 25th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.09. The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $0.80 million. Mediwound had a negative return on equity of 398.49% and a negative net margin of 31.08%. On average, analysts expect Mediwound to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Shares of MDWD stock opened at $4.30 on Wednesday. The company has a market capitalization of $117.14 million, a price-to-earnings ratio of -8.78 and a beta of 0.70. Mediwound has a fifty-two week low of $3.76 and a fifty-two week high of $7.35.

A number of equities research analysts have weighed in on MDWD shares. Oppenheimer set a $15.00 target price on Mediwound and gave the stock a “buy” rating in a report on Tuesday, January 22nd. Zacks Investment Research upgraded Mediwound from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a report on Thursday, January 24th.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2019/05/15/mediwound-mdwd-to-release-quarterly-earnings-on-tuesday.html.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: Should you buy a closed-end mutual fund?

Earnings History for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply